10
Sep
2026
Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
Sometimes drug candidates fail in the most surprising and painful ways. Even after everything looks good in early and mid-stage clinical trials, and with capable hands on the wheel. Ask Novartis. Two weeks ago, few would have predicted the back-to-back Phase III failures of Novartis’ lipoprotein A-directed oligonucleotide for cardiovascular disease and the antibody oligonucleotide conjugate for myotonic dystrophy type... Read More